Status:
RECRUITING
Dose-staged Gamma Knife Radiosurgery Versus Microsurgical Resection
Lead Sponsor:
Medical University of Vienna
Conditions:
Brain Metastases
Eligibility:
All Genders
18-90 years
Phase:
NA
Brief Summary
Background. Brain metastases (BM) are the most common intracranial tumor and occur in 20-40% of all oncological patients. The most common primary cancer in brain metastases is lung cancer, followed by...
Eligibility Criteria
Inclusion
- Patients over 18 years and under 90 years
- Patients with KPS ≥70
- Patients with NSCLC, melanoma, breast cancer or renal cancer as primary tumor
- Maximum of three brain metastases on the diagnostic MRI
- Tumor volume of 8-20 ccm3 on the diagnostic MRI
- Lobular brain metastases
- Patients without any contraindications for both treatment options
- Written, signed informed consent for study particaption after study explanation
Exclusion
- Patients under 18 years and over 90 years
- Patients with KPS \<70
- Patients with other primary tumor
- More than three brain metastases on the diagnostic MRI
- Tumor volume \<8 or \>20 ccm3 on the diagnostic MRI
- Patients with contraindications for both treatment options
Key Trial Info
Start Date :
July 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04857905
Start Date
July 1 2020
End Date
December 1 2025
Last Update
January 5 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Neurosurgery, Medical University of Vienna
Vienna, Austria, 1090